article thumbnail

Cardiogenic Shock in Older Adults: A Focus on Age-Associated Risks and Approach to Management: A Scientific Statement From the American Heart Association

Circulation

Cardiogenic shock continues to portend poor outcomes, conferring short-term mortality rates of 30% to 50% despite recent scientific advances. Age is a nonmodifiable risk factor for mortality in patients with cardiogenic shock and is often considered in the decision-making process for eligibility for various therapies.

article thumbnail

Lymphomonocytic inflammatory infiltrate with numerous eosinophilic granulocytes in the interstitium in a surviving heart transplant recipient: a case report

Frontiers in Cardiovascular Medicine

Eosinophilic myocarditis (EM), a rare condition, is fatal if left untreated and has rarely been described in heart transplant recipients. The cornerstone of treatment is corticosteroids, comprehensive therapy and heart failure management (including advanced mechanical support for fulminant myocarditis).

article thumbnail

Abstract 4146823: Trends and Outcomes in Heart Failure Admissions and Cardiogenic Shock Among Patients with Congenital Heart Disease

Circulation

Cardiogenic shock rates were highest among SV-CHD patients, with significant fluctuations, followed by DV-CHD patients. Heart transplant rates were low but increased slightly in 2020 for patients without CHD, with DV and SV CHD patients showing fluctuating rates peaking in 2018 and 2019, then declining in 2020.

article thumbnail

Heart transplantation under mechanical circulatory support for fulminant myocarditis: a Case Report

Journal of Cardiothoracic Surgery

Fulminant myocarditis has been defined as the clinical manifestation of cardiac inflammation with rapid-onset heart failure and cardiogenic shock. We report on the case of a 17-year-old boy with hemodynamic de.

article thumbnail

Midterm outcomes of patients with native heart recovery after Impella 5+ for cardiogenic shock

European Journal of Heart Failure

Abstract Aims Left ventricular unloading by percutaneous microaxial flow-pump devices has been shown to improve survival in patients with cardiogenic shock (CS). 5+) support is effective in facilitating heart recovery, overall survival, and quality of life. years, 80% male) received Impella 5+ and discharged with heart recovery.

article thumbnail

Heart Pump Improves Survival After Severe Heart Attacks

DAIC

milla1cf Mon, 04/08/2024 - 18:07 April 8, 2024 — Implantation of the Impella CP micro-axial flow pump in the hours after a heart attack significantly increased the rate of survival at six months among people suffering cardiogenic shock, according to a study presented at the American College of Cardiology ’s Annual Scientific Session.

article thumbnail

Impact of Advanced Therapy Centers on Characteristics and Outcomes of Heart Failure Admissions

Circulation: Heart Failure

Centers performing at least 1 heart transplant or left ventricular assist device were classified as ATCs. A secondary analysis evaluated outcomes for severe HF hospitalizations (cardiogenic shock, cardiac arrest, and mechanical ventilation). of centers), 525 037 (18.3%) were admissions to ATCs (5.5%